Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Samsung Affiliates Aim For IPO, Biologics Expansion

This article was originally published in PharmAsia News

Executive Summary

Samsung Group's two biopharma affiliates are aiming high to become global leaders in the development of biosimilars and production of biomedicines. Although the largest South Korean conglomerate is a late starter compared to other biosimilar rivals including Celltrion, its affiliates Samsung Bioepis and Samsung Biologics have been making rapid progress on the back of strong group-wide support.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts